David Kandath, MD
Cardiovascular Disease · Saratoga Springs, NYNPI 1609832096
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novartis at 51.4% of the total. Reporting peaked in 2024 at $551 and has fallen 55.8% since, to $243 in 2025.
Across 131 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Sanofi-aventis U.S. LLC$251
- Kiniksa Pharmaceuticals International, PLC$176
- Novo Nordisk$172
- Kiniksa Pharmaceuticals, Ltd.$101
- Astellas Pharma US Inc$100
- plus $188 from 10 others
Across 519 payments — averaging $3057.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$446K
- Eli Lilly$362K
- Novo Nordisk AS$212K
- Amgen$171K
- AstraZeneca$110K
- Boehringer Ingelheim Pharma GmbH & Co.kg$85K
- plus $201K from 5 others
What the payments were for
- Food & beverage$1,93195%
- Education$1005%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 90 | $1,043 |
| Sanofi-aventis U.S. LLC | 10 | $251 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $176 |
| Novo Nordisk | 9 | $172 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $101 |
| Astellas Pharma US Inc | 1 | $100 |
| Amgen | 2 | $30 |
| Tactile Systems Technology Inc | 1 | $23 |
| Altathera Pharmaceuticals LLC | 1 | $23 |
| Bayer | 1 | $19 |
| Abbott | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Pfizer | 1 | $11 |
How this compares
$2,031 in reported general payments places this provider in the 55th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 692 | $898,806 |
| MultaqDronedarone Hcl | 220 | $393,279 |
| OzempicSemaglutide | 277 | $376,330 |
| JardianceEmpagliflozin | 237 | $303,053 |
| XareltoRivaroxaban | 177 | $236,253 |
| FarxigaDapagliflozin Propanediol | 148 | $183,408 |
| Repatha SureclickEvolocumab | 149 | $170,708 |
| EntrestoSacubitril/Valsartan | 85 | $117,343 |
| RybelsusSemaglutide | 22 | $42,088 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $41,417 |
| Praluent PenAlirocumab | 45 | $33,642 |
| Rosuvastatin Calcium | 1,628 | $32,113 |
| Ezetimibe | 757 | $29,385 |
| MounjaroTirzepatide | 17 | $23,851 |
| TrulicityDulaglutide | 15 | $21,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $11 | $898,806692 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $172 | $436,146312 claims |
| Sanofi-aventis U.S. LLCMultaq | $251 | $393,279220 claims |
| Johnson & JohnsonXarelto | $14 | $236,253177 claims |
| AstraZenecaFarxiga | $16 | $183,408148 claims |
| NovartisEntresto | $1,043 | $117,34385 claims |
| Lilly USA, LLCMounjaro, Trulicity | $17 | $45,49632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Saratoga Springs
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.